A randomized phase II chemoprevention trial of 13-cis retinoic acid with or without α tocopherol or observation in subjects at high risk for lung cancer

Cancer Prevention Research

Volumn 2, Issue 5, 2009, Pages 440-449

  Kelly, Karen ^a   Kittelson, John ^b   Franklin, Wilbur A ^b   Kennedy, Timothy C ^d   Klein, Catherine E ^a,c   Keith, Robert L ^b,c   Dempsey, Edward C ^b,c   Lewis, Marina ^a,b   Jackson, Mary K ^a   Hirsch, Fred R ^a,b   Bunn, Paul A ^a   Miller, York E ^b,c  

^a UNIVERSITY OF COLORADO SCHOOL OF MEDICINE   (United States)

^b UNIVERSITY OF COLORADO   (United States)

^c VETERANS AFFAIRS MEDICAL CENTER   (United States)

^d UNIVERSITY OF COLORADO CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA TOCOPHEROL; ISOTRETINOIN; KI 67 ANTIGEN; ANTINEOPLASTIC AGENT; TOCOPHEROL;

ADULT; AGED; ANAMNESIS; ANTIBODY LABELING; ARTICLE; BLEEDING; BRONCHOSCOPY; BRONCHUS BIOPSY; CANCER COMBINATION CHEMOTHERAPY; CARDIOPULMONARY ARREST; CELL PROLIFERATION; CHEMOPROPHYLAXIS; CHOLESTEROL BLOOD LEVEL; CLINICAL EVALUATION; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DISEASE COURSE; DRUG EFFECT; DRUG FATALITY; DRUG WITHDRAWAL; DRY EYE; DRY SKIN; FEMALE; FOLLOW UP; GASTROINTESTINAL TOXICITY; HEART FAILURE; HIGH RISK PATIENT; HISTOLOGY; HUMAN; HYPERGLYCEMIA; INVASIVE CARCINOMA; LIVER DYSFUNCTION; LUNG CANCER; MAJOR CLINICAL STUDY; MALE; MUSCULOSKELETAL DISEASE; OBSERVATION; OUTCOME ASSESSMENT; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RESPIRATORY FAILURE; SIDE EFFECT; THERAPY EFFECT; TREATMENT DURATION; TREATMENT FAILURE; TRIACYLGLYCEROL BLOOD LEVEL; URIC ACID BLOOD LEVEL; LUNG; LUNG TUMOR; MIDDLE AGED; RISK FACTOR; SMOKING; TUMOR RECURRENCE;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; BRONCHOSCOPY; FEMALE; HUMANS; ISOTRETINOIN; LUNG; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; RISK FACTORS; SMOKING; TOCOPHEROLS;

EID: 67650281998     PISSN: 19406207     EISSN: None     Source Type: Journal    
DOI: 10.1158/1940-6207.CAPR-08-0136     Document Type: Article

References (40)

1. Jemal A, Siegel R, Ward E, et al. Cancer statistics, 2008. CA Cancer J Clin 2008;58:71-96.
2. Anthonisen NR, Skeans MA, Wise RA, Manfreda J, Kanner RE, Connett JE. The effects of a smoking cessation intervention on 14.5-year mortality: a randomized clinical trial. Ann Intern Med 2005;142: 233-239 (Pubitemid 40216240)
3. Tong L, Spitz MR, Fueger JJ, Amos CA. Lung carcinoma in former smokers. Cancer 1996;78: 1004-1010
4. Sporn MB, Dunlop NM, Newton DL, Smith JM. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed Proc 1976;35:1332-1338.
5. Fisher B, Costantino JP, Wickerham DL, et al. Tamoxifen for the prevention of breast cancer: current status of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 2005; 97:1652-1662 (Pubitemid 41672231)
6. Vogel VG, Costantino JP, Wickerham DL, et al. Effects of tamoxifen vs raloxifene on the risk of developing invasive breast cancer and other disease outcomes: the NSABP Study of Tamoxifen and Raloxifene (STAR) P-2 trial. JAMA 2006;295:2727-2741
7. Thompson IM, Goodman PJ, Tangen CM, et al. The influence of finasteride on the development of prostate cancer. N Engl J Med 2003;349:215-224 (Pubitemid 36859473)
8. Giardiello FM, Yang VW, Hylind LM, et al. Primary chemoprevention of familial adenomatous polyposis with sulindac. N Engl J Med 2002;346:1054-1059
9. Steinbach G, Lynch PM, Phillips RK, et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N Engl J Med 2000;342:1946-1952 (Pubitemid 30419089)
10. Saccomanno G, Moran PG, Schmidt R, et al. Effects of 13-CIS retinoids on premalignant and malignant cells of lung origin. Acta Cytol 1982; 26:78-85. (Pubitemid 12169607)
11. Nicholson AG, Perry LJ, Cury PM, et al. Reproducibility of the WHO/IASLC grading system for pre-invasive squamous lesions of the bronchus: a study of inter-observer and intra-observer variation. Histopathology 2001;38:202-208
12. Omenn GS, Goodman GE, Thomquist MD, et al. Effects of a combination of β carotene and vitamin A on lung cancer and cardiovascular disease. N Engl J Med 1996;334:1150-1155 (Pubitemid 26137973)
13. The α-Tocopherol, β Carotene Cancer Prevention Study Group. The effect of vitamin E and β carotene on the incidence of lung cancer and other cancers in male smokers. N Engl J Med 1994;330: 1029-1035.
14. Kamangar F, Qiao YL, Yu B, et al. Lung cancer chemoprevention: a randomized, double-blind trial in Linxian, China. Cancer Epidemiol Biomarkers Prev 2006;15:1562-1564. (Pubitemid 44299334)
15. Lippman SM, Lee JJ, Karp DD, et al. Randomized phase III intergroup trial of isotretinoin to prevent second primary tumors in stage I non-small-cell lung cancer. J Natl Cancer Inst 2001;93:605-618
16. van Zandwijk N, Dalesio O, Pastorino U, de Vries N, van Tinteren H. EUROSCAN, a randomized trial of vitamin A and N-acetylcysteine in patients with head and neck cancer or lung cancer. For the European Organization for Research and Treatment of Cancer Head and Neck and Lung Cancer Cooperative Groups. J Natl Cancer Inst 2000;92:977-986
17. O'Shaughnessy JA, Kelloff GJ, Gordon GB, et al. Treatment and prevention of intraepithelial neoplasia: an important target for accelerated new agent development. Clin Cancer Res 1989;8:314-346
18. Prentice RL. Surrogate endpoints in clinical trials: definition and operational criteria. Stat Med 2002;8: 431-440
19. Berger VW. Does the Prentice criterion validate surrogate endpoints? Stat Med 2004;23:1571-1578
20. McLarty JW, Holiday DB, Girard WM, Yanagihara RH, Kummet TD, Greenberg SD. β-Carotene, vitamin A, lung cancer chemoprevention: results of an intermediate endpoint study. Am J Clin Nutr 1995; 62:1431S-8S.
21. Kurie JM, Lee JS, Khuri FR, et al. N-(4-hydroxyphenyl)retinamide in the chemoprevention of squamous metaplasia and dysplasia of the bronchial epithelium. Clin Cancer Res 2000;6:2973-2979
22. Lam S, MacAulay C, Le Riche JC, et al. A randomized phase IIb trial of anethole dithiolethione in smokers with bronchial dysplasia. J Natl Cancer Inst 2002;94:1001-1009 (Pubitemid 34814729)
23. Lam S, leRiche JC, McWilliams A, et al. A randomized phase IIb trial of pulmicort turbuhaler (budesonide) in people with dysplasia of the bronchial epithelium. Clin Cancer Res 2004;10:6502-6511
24. van den Berg RM, van TH, van ZN, et al. The influence of fluticasone inhalation on markers of carcinogenesis in bronchial epithelium. Am J Respir Crit Care Med 2007;175:1061-1065
25. Kelloff GJ, Lippman SM, Dannenberg AJ, et al. Progress in chemoprevention drug development: the promise of molecular biomarkers for prevention of intraepithelial neoplasia and cancer-a plan to move forward. Clin Cancer Res 2006;12:3661-3697
26. Szabo E. Lung epithelial proliferation: a biomarker for chemoprevention trials? J Natl Cancer Inst 2001;93:1042-1043
27. Lee JJ, Liu D, Lee JS, et al. Long-term impact of smoking on lung epithelial proliferation in current and former smokers. J Natl Cancer Inst 2001;93: 1081-1088 (Pubitemid 32717540)
28. Mao JT, Fishbein MC, Adams B, et al. Celecoxib decreases Ki-67 proliferative index in active smokers. Clin Cancer Res 2006;12:314-320 (Pubitemid 43166209)
29. Hittelman WN, Liu DD, Kurie JM, et al. Proliferative changes in the bronchial epithelium of former smokers treated with retinoids. J Natl Cancer Inst 2007;99:1603-1612
30. Lam S, leRiche JC, Zheng Y, et al. Sex-related differences in bronchial epithelial changes associated with tobacco smoking. J Natl Cancer Inst 1999;91:691-696
31. Miller YE, Blatchford P, Hyun DS, et al. Bronchial epithelial Ki-67 index is related to histology, smoking, and gender, but not lung cancer or chronic obstructive pulmonary dis- ease. Cancer Epidemiol Biomarkers Prev 2007; 16:2425-2431 (Pubitemid 351196376)
32. Shklar G, Flynn E, Szabo G, Marefat P. Retinoid inhibition of experimental lingual carcinogenesis: ultrastructural observations. J Natl Cancer Inst 1980;65:1307-1316 (Pubitemid 11196022)
33. Lippman SM, Batsakis JG, Toth BB, et al. Comparison of low-dose isotretinoin with β carotene to prevent oral carcinogenesis. N Engl J Med 1993; 328:15-20. (Pubitemid 23011466)
34. Hong WK, Endicott J, Itri LM, et al. 13-cis-retinoic acid in the treatment of oral leukoplakia. N Engl J. Med 1986;315:1501-1505 (Pubitemid 17052146)
35. Xu XC, Lee JS, Lee JJ, et al. Nuclear retinoid acid receptor β in bronchial epithelium of smokers before and during chemoprevention. J Natl Cancer Inst 1999;91:1317-1321
36. Kurie JM, Lotan R, Lee JJ, et al. Treatment of former smokers with 9-cis-retinoic acid reverses loss of retinoic acid receptor-β expression in the bronchial epithelium: results from a randomized placebo-controlled trial. J Natl Cancer Inst 2003;95:206-214 (Pubitemid 36240633)
37. Dimery IW, Hong WK, Lee JJ, et al. Phase I trial of α-tocopherol effects on 13-cis-retinoic acid toxicity. Ann Oncol 1997;8:85-89 (Pubitemid 27112807)
38. Green S, Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992;10:239-253 (Pubitemid 23008970)
39. Hirsch FR, Prindiville SA, Miller YE, et al. Fluorescence versus white-light bronchoscopy for detection of preneoplastic lesions: a randomized study. J Natl Cancer Inst 2001;93:1385-1391
40. Merrick DT, Kittelson J, Winterhalder R, et al. Analysis of c-ErbB1/epidermal growth factor receptor and c-ErbB2/HER-2 expression in bronchial dysplasia: evaluation of potential targets for chemoprevention of lung cancer. Clin Cancer Res 2006;12:2281-2288